Creo Medical
Creo Medical, a pioneering medical device company headquartered in Great Britain, is at the forefront of advanced energy-based surgical solutions. Founded in 2015, the company has rapidly established itself in the medical technology industry, focusing on innovative treatments for gastrointestinal and oncological conditions. With a strong presence in Europe and expanding operations in the United States and Asia, Creo Medical is renowned for its unique combination of microwave and radiofrequency technologies. Their flagship products, including the CROMA™ and the Speedboat™ devices, offer minimally invasive options that enhance patient outcomes and reduce recovery times. Recognised for its commitment to innovation, Creo Medical has achieved significant milestones, positioning itself as a leader in the field of surgical endoscopy. The company continues to drive advancements in medical technology, making a meaningful impact on patient care worldwide.
DitchCarbon Score
How does Creo Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Creo Medical's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Creo Medical's reported carbon emissions
In 2024, Creo Medical reported total carbon emissions of approximately 1,045,200 kg CO2e, comprising 354,200 kg CO2e from Scope 1 (mobile combustion), 85,200 kg CO2e from Scope 2 (purchased electricity), and 600,800 kg CO2e from Scope 3 (business travel). In 2023, the company’s emissions were about 585,500 kg CO2e, with Scope 1 emissions at 46,500 kg CO2e, Scope 2 at 26,500 kg CO2e, and Scope 3 at 533,000 kg CO2e. Creo Medical has set ambitious climate commitments, aiming for a minimum annual emissions reduction of 7% across all scopes from 2023 to 2030. Additionally, the company targets achieving net-zero emissions for both Scope 1 and Scope 2 by 2027. This commitment reflects a proactive approach to mitigating climate impact and aligns with industry standards for sustainability. The emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Creo Medical Group PLC. The company continues to focus on reducing its carbon footprint while enhancing operational efficiency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 207,400 | 000,000 |
| Scope 2 | 67,300 | 00,000 |
| Scope 3 | 263,700 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Creo Medical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
